Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTINE THAI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1043224587
CMS profile
1470
Location
HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$874.35

56 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $874.35 56

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTINE THAI

NPI 1043224587 · CMS profile ID 1470

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043224587?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043224587?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043224587?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1043224587?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

56 matching records · $874.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 56 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 56.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $11.4912/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432525 CMS
Novartis Pharmaceuticals Corporation $16.4712/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415635 CMS
Amgen Inc. $10.2812/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432523 CMS
ABBVIE INC. $9.4612/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515801 CMS
Amgen Inc. $5.0312/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432477 CMS
Novartis Pharmaceuticals Corporation $16.5611/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415633 CMS
Amgen Inc. $8.8711/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432521 CMS
Amgen Inc. $21.1811/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432495 CMS
ABBVIE INC. $18.7310/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515797 CMS
UCB, Inc. $18.0710/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965190347 CMS
Organon LLC $8.1710/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022232155 CMS
Amgen Inc. $23.4310/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432519 CMS
Novartis Pharmaceuticals Corporation $16.2610/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415631 CMS
Amgen Inc. $11.8909/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432493 CMS
Amgen Inc. $11.0309/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432517 CMS
Novartis Pharmaceuticals Corporation $13.5109/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415629 CMS
ABBVIE INC. $8.4009/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515793 CMS
Amgen Inc. $15.3409/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432515 CMS
ABBVIE INC. $7.2709/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515789 CMS
Amgen Inc. $7.3109/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432491 CMS
Novartis Pharmaceuticals Corporation $19.4008/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415627 CMS
Amgen Inc. $6.7508/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432489 CMS
Amgen Inc. $18.7507/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432487 CMS
Amgen Inc. $14.3907/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432513 CMS
Novartis Pharmaceuticals Corporation $15.5207/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415625 CMS
Amgen Inc. $27.3207/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432511 CMS
Organon LLC $7.2507/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022232141 CMS
ABBVIE INC. $4.4007/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515787 CMS
ABBVIE INC. $10.6806/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515783 CMS
Amgen Inc. $12.7306/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432503 CMS
GlaxoSmithKline, LLC. $18.0206/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945127825 CMS
Amgen Inc. $4.2805/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432501 CMS
Novartis Pharmaceuticals Corporation $17.6205/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415623 CMS
ABBVIE INC. $28.3205/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515779 CMS
Amgen Inc. $7.7405/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432499 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.4805/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887373407 CMS
Amgen Inc. $5.0905/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432479 CMS
ABBVIE INC. $12.7704/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515775 CMS
Novartis Pharmaceuticals Corporation $21.5904/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415621 CMS
ABBVIE INC. $7.6604/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515771 CMS
Amgen Inc. $9.2304/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432509 CMS
ABBVIE INC. $11.6003/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515765 CMS
ABBVIE INC. $125.0003/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515769 CMS
Amgen Inc. $7.1603/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432485 CMS
Novartis Pharmaceuticals Corporation $15.7003/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415619 CMS
Aurinia Pharma U.S., Inc. $29.0003/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954105767 CMS
Amgen Inc. $22.7803/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432483 CMS
Amgen Inc. $4.1503/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432507 CMS
Organon LLC $6.1403/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022232149 CMS
Amgen Inc. $4.6102/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432481 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,357.35 137
PY2020 $1,472.25 78
PY2021 $298.93 19
PY2022 $874.35 56
PY2023 $974.73 69
PY2024 $693.01 43
PY2025 $811.99 35

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,372,053.89 61
PY2024 Recipient $8,444.46 4
PY2024 Principal investigator $1,430,507.12 79
PY2023 Recipient $8,498.49 1
PY2023 Principal investigator $1,858,436.22 86
PY2022 Recipient $72,841.00 2
PY2022 Principal investigator $1,860,641.35 160
PY2021 Recipient $2,012.04 2
PY2021 Principal investigator $577,779.35 91
PY2020 Recipient $2,580.07 2
PY2020 Principal investigator $908,629.40 110
PY2019 Recipient $16,824.73 4
PY2019 Principal investigator $518,505.93 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

93 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $808.40 12/28/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792488435
Recipient Eli Lilly and Company $16.15 12/17/2021 Covered Recipient Physician A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 819443765
Principal investigator 1 Eli Lilly and Company $1,007.09 12/16/2021 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, TWO-ARM, PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 819461571
Principal investigator 1 ABBVIE INC. $680.00 12/15/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) No dispute reported 06/30/2026 792487141
Principal investigator 1 ABBVIE INC. $19,589.70 12/07/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) No dispute reported 06/30/2026 792485743
Principal investigator 1 ABBVIE INC. $2,669.65 12/02/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792485133
Principal investigator 1 ABBVIE INC. $75.60 12/02/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792485275
Principal investigator 1 Eli Lilly and Company $15,000.00 11/22/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819453211
Principal investigator 1 ABBVIE INC. $12,789.40 11/18/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) No dispute reported 06/30/2026 792483637
Principal investigator 1 ABBVIE INC. $4,663.84 11/18/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792483821
Principal investigator 1 ABBVIE INC. $416.00 11/17/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 792482867
Principal investigator 1 ABBVIE INC. $157.95 11/17/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792483359
Principal investigator 1 ABBVIE INC. $2,082.00 11/17/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) No dispute reported 06/30/2026 792483463
Principal investigator 1 ABBVIE INC. $8,048.05 11/10/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792482523
Principal investigator 1 ABBVIE INC. $3,181.30 11/04/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792481305
Principal investigator 1 ABBVIE INC. $10,000.00 11/03/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment No dispute reported 06/30/2026 792480925
Principal investigator 1 Eli Lilly and Company $561.92 10/26/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 819460511
Principal investigator 1 ABBVIE INC. $2,653.80 10/14/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792479629
Principal investigator 1 ABBVIE INC. $4,393.00 10/14/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792479719
Principal investigator 1 ABBVIE INC. $4,823.92 10/14/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) No dispute reported 06/30/2026 792479833
Recipient Eli Lilly and Company $1,995.89 10/08/2021 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819443663
Principal investigator 1 ABBVIE INC. $11,468.68 10/06/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792477631
Principal investigator 1 ABBVIE INC. $1,896.72 10/06/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792477633
Principal investigator 1 ABBVIE INC. $1,739.26 10/06/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 No dispute reported 06/30/2026 792477885
Principal investigator 1 ABBVIE INC. $200.00 09/14/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 792475439
Principal investigator 1 ABBVIE INC. $11,736.90 09/09/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792475133
Principal investigator 1 ABBVIE INC. $8,775.70 09/09/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792475201
Principal investigator 1 ABBVIE INC. $630.25 09/09/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792475295
Principal investigator 1 ABBVIE INC. $6,155.54 09/01/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792473755
Principal investigator 1 ABBVIE INC. $1,896.72 08/30/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792473179
Principal investigator 1 ABBVIE INC. $48.27 08/18/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792472313
Principal investigator 1 ABBVIE INC. $12,403.80 08/13/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792472131
Principal investigator 1 ABBVIE INC. $2,080.00 07/29/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 792468989
Principal investigator 1 ABBVIE INC. $9,500.00 07/29/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) No dispute reported 06/30/2026 792469177
Principal investigator 1 ABBVIE INC. $5,426.70 07/29/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792470243
Principal investigator 1 ABBVIE INC. $8,462.40 07/29/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792470245
Principal investigator 1 ABBVIE INC. $6,295.10 07/29/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792470601
Principal investigator 1 ABBVIE INC. $4,323.44 07/29/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) No dispute reported 06/30/2026 792470959
Principal investigator 1 ABBVIE INC. $3,646.72 07/29/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 No dispute reported 06/30/2026 792471245
Principal investigator 1 ABBVIE INC. $1,625.30 07/14/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792467623
Principal investigator 1 ABBVIE INC. $205.63 07/12/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792467393
Principal investigator 1 ABBVIE INC. $2,141.44 06/30/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 792464515
Principal investigator 1 ABBVIE INC. $7,534.75 06/30/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792465237
Principal investigator 1 ABBVIE INC. $1,321.65 06/30/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792465587
Principal investigator 1 ABBVIE INC. $1,427.92 06/30/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) No dispute reported 06/30/2026 792465901
Principal investigator 1 ABBVIE INC. $2,755.58 06/30/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 No dispute reported 06/30/2026 792466209
Principal investigator 1 ABBVIE INC. $2,682.88 06/08/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 792462417
Principal investigator 1 ABBVIE INC. $1,683.92 06/08/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) No dispute reported 06/30/2026 792462731
Principal investigator 1 ABBVIE INC. $7,971.15 06/02/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792461663
Principal investigator 1 ABBVIE INC. $3,246.10 05/27/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792460845
Principal investigator 1 ABBVIE INC. $1,983.74 05/27/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 No dispute reported 06/30/2026 792461209
Principal investigator 1 ABBVIE INC. $12,403.80 05/20/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792458799
Principal investigator 1 ABBVIE INC. $1,289.20 05/05/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792453879
Principal investigator 1 ABBVIE INC. $1,683.92 05/03/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) No dispute reported 06/30/2026 792453229
Principal investigator 1 ABBVIE INC. $7,119.95 04/30/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792452503
Principal investigator 1 ABBVIE INC. $16,728.57 04/29/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792450083
Principal investigator 1 ABBVIE INC. $5,982.00 04/29/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792450089
Principal investigator 1 ABBVIE INC. $11,500.00 04/22/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792446711
Principal investigator 1 Eli Lilly and Company $32,366.00 04/19/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 819463661
Principal investigator 1 ABBVIE INC. $250.00 04/13/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 No dispute reported 06/30/2026 792444937
Principal investigator 1 ABBVIE INC. $10,748.18 04/02/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792442109
Principal investigator 1 ABBVIE INC. $4,878.96 04/01/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) No dispute reported 06/30/2026 792441727
Principal investigator 1 Eli Lilly and Company $33,495.00 04/01/2021 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 819450177
Principal investigator 1 ABBVIE INC. $2,125.82 03/31/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 792439673
Principal investigator 1 ABBVIE INC. $4,085.28 03/30/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792437951
Principal investigator 1 ABBVIE INC. $10,665.40 03/30/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792438519
Principal investigator 1 ABBVIE INC. $1,682.94 03/30/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 No dispute reported 06/30/2026 792439533
Principal investigator 1 Eli Lilly and Company $4,472.85 03/25/2021 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 819457877
Principal investigator 1 ABBVIE INC. $5,400.00 03/18/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 792434069
Principal investigator 1 ABBVIE INC. $8,625.00 03/18/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 792434077
Principal investigator 1 Eli Lilly and Company $518.65 03/08/2021 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 819457881
Principal investigator 1 ABBVIE INC. $750.00 03/04/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 792431897
Principal investigator 1 ABBVIE INC. $186.00 03/04/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792431979
Principal investigator 1 ABBVIE INC. $500.00 03/04/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 No dispute reported 06/30/2026 792432081
Principal investigator 1 ABBVIE INC. $1,625.30 03/03/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792431707
Principal investigator 1 ABBVIE INC. $2,956.54 03/02/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 792426687
Principal investigator 1 ABBVIE INC. $10,679.35 03/02/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792429611
Principal investigator 1 ABBVIE INC. $1,896.72 03/02/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792429617
Principal investigator 1 ABBVIE INC. $6,809.45 03/02/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792430291
Principal investigator 1 ABBVIE INC. $2,500.86 03/02/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 No dispute reported 06/30/2026 792431287
Principal investigator 1 ABBVIE INC. $18,124.74 02/12/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period No dispute reported 06/30/2026 792423153
Principal investigator 1 ABBVIE INC. $4,779.00 02/12/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792423171
Principal investigator 1 ABBVIE INC. $5,325.82 01/28/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 792413065
Principal investigator 1 ABBVIE INC. $5,854.72 01/28/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) No dispute reported 06/30/2026 792415887
Principal investigator 1 ABBVIE INC. $8,256.33 01/28/2021 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 792416773
Principal investigator 1 ABBVIE INC. $2,307.68 01/28/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 No dispute reported 06/30/2026 792418567
Principal investigator 1 ABBVIE INC. $250.00 01/27/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) No dispute reported 06/30/2026 792413005
Principal investigator 1 Eli Lilly and Company $25,232.00 01/26/2021 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 819461417
Principal investigator 1 Eli Lilly and Company $442.65 01/26/2021 Non-covered Recipient Entity
VANCOUVER CLINIC INC PS
A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 819470173
Principal investigator 1 ABBVIE INC. $2,895.52 01/25/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) No dispute reported 06/30/2026 792412141
Principal investigator 1 ABBVIE INC. $748.27 01/13/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 No dispute reported 06/30/2026 792408999
Principal investigator 1 Eli Lilly and Company $5,174.00 01/12/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 819452617
Principal investigator 1 Eli Lilly and Company $69,595.00 01/04/2021 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENTING SARS COV 2 INFECTION AND COVID 19 IN SKILLED NURSING AND ASSISTED LIVING FACILITY RESIDENTS AND STAFF A NIAID AND LILLY COLLABORATIVE STUDY No dispute reported 06/30/2026 819452357